FacebookTwitterRedditEmail

Selling One Pill to Treat Side Effects of Another Pill

Nearly one in four US women is on antidepressants. The drugs, like Prozac, Paxil and Zoloft, may be happy pills but they are not happy-in-the-bedroom pills. Both older and newer antidepressants cause severe sexual dysfunction like diminished libido and anorgasmia, the inability to achieve orgasm, even with adequate stimulation.

Antidepressant sexual dysfunction is so common, it is used as a sales pitch by the drug manufacturers. “Wellbutrin X works for my depression with a low risk of weight gain and sexual side effects,” say glossy magazine ads showing young men whose sexuality is intact thanks to a better antidepressant. “Can your medicine do all that?” One study found 96 percent patients on a particular antidepressant developed anorgasmia. Who likes those statistics?

Now, marketers of two new sex drugs for women are acknowledging how many women are actually on antidepressants. A Dutch company developing the female libido drugs, Lybrido and Lybridos (which are not yet FDA approved or available) believes the drugs may help the antidepressant-related sexual problems, according to an article in the New York Times magazine. Lybrido contains two possible libido enhancers for women, testosterone and sildenafil, the active ingredient in Viagra. But Lybridos contains testosterone and the antidepressant buspirone, a drug already on the market and known to reverse the negative sexual side effects of antidepressants in some cases by modifying changed levels of the neurotransmitter serotonin that cause the sexual dysfunction.

Buspirone is similar to a “female Viagra” drug that almost reached the market a few years ago. Flibanserin, made by the German company Boehringer Ingelheim, was intended to treat “hypoactive sexual desire disorder” in women but rejected by the FDA. Flibanserin was similar to the antidepressant Serzone which is linked to hyper sexual arousal and the abnormal and painful erectile state known as priapism. Serzone has been withdrawn from markets.

Like Viagra (which had been intended to be an angina drug until its erectile effects appeared) flibanserin, the drug rejected three years ago, was groomed to be an antidepressant drug until its effect on female sexual desire surfaced. Some trial participants did not want to surrender their unused pills at the end of the study. But, despite medical and media excitement about flibanserin and pleas from Big Pharma, Wall Street, husbands, boyfriends and women, the FDA rejected flibanserin in 2010–not for its side effects like dizziness, nausea and sleepiness but because it didn’t seem to work.

Thanks to Big Pharma marketing, Americans increasingly seek a quick fix for “depression,” “sexual dysfunction” and other lifestyle problems. Before direct to consumer marketing of antidepressants, people did not expect to be deliriously happy for no reason or term their problems with marriages and relationships, jobs, health and money, “depression.” Medicalizing lifestyle problems is a cash cow for Big Pharma because advertising works.

Of course, there is no assurance that Lybrido and Lybridos will be approved by the FDA or gain acceptance among doctors and women. But if they do, Big Pharma’s audacious business model of selling one expensive pill to treat side effects of another expensive pill will surely please Wall Street.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

 

More articles by:

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

bernie-the-sandernistas-cover-344x550
September 19, 2019
Richard Falk
Burning Amazonia, Denying Climate Change, Devastating Syria, Starving Yemen, and Ignoring Kashmir
Charles Pierson
With Enemies Like These, Trump Doesn’t Need Friends
Lawrence Davidson
The Sorry State of the Nobel Peace Prize
Evaggelos Vallianatos
The Scourge in the White House
Urvashi Sarkar
“Not a Blade of Grass Grew:” Living on the Edge of the Climate Crisis in the Sandarbans of West Bengal.
Thomas Knapp
Trump and Netanyahu: “Mutual Defense” or Just Mutual Political Back-Scratching?
Dean Baker
Is There Any Lesser Authority Than Alan Greenspan?
Gary Leupp
Warren’s Ethnic Issue Should Not Go Away
George Ochenski
Memo to Trump: Water Runs Downhill
Jeff Cohen
What George Carlin Taught Us about Media Propaganda by Omission
Stephen Martin
The Perspicacity of Mcluhan and Panopticonic Plans of the MIC
September 18, 2019
Kenneth Surin
An Excellent Study Of The Manufactured Labour “Antisemitism Crisis”
Patrick Cockburn
The Saudi Crown Prince Plans to Make Us Forget About the Murder of Jamal Khashoggi Before the US Election
W. T. Whitney
Political Struggle and Fixing Cuba’s Economy
Ron Jacobs
Support the Climate Strike, Not a Military Strike
John Kendall Hawkins
Slouching Toward “Bethlehem”
Ted Rall
Once Again in Afghanistan, the U.S. Proves It Can’t Be Trusted
William Astore
The Ultra-Costly, Underwhelming F-35 Fighter
Dave Lindorff
Why on Earth Would the US Go to War with Iran over an Attack on Saudi Oil Refineries?
Binoy Kampmark
Doctored Admissions: the University Admissions Scandal as a Global Problem
Jeremy Corbyn
Creating a Society of Hope and Inclusion: Speech to the TUC
Zhivko Illeieff
Why You Should Care About #ShutDownDC and the Global Climate Strike  
Catherine Tumber
Land Without Bread: the Green New Deal Forsakes America’s Countryside
Liam Kennedy
Boris Johnson: Elitist Defender of Britain’s Big Banks
September 17, 2019
Mario Barrera
The Southern Strategy and Donald Trump
Robert Jensen
The Danger of Inspiration in a Time of Ecological Crisis
Dean Baker
Health Care: Premiums and Taxes
Dave Lindorff
Recalling the Hundreds of Thousands of Civilian Victims of America’s Endless ‘War on Terror’
Binoy Kampmark
Oiling for War: The Houthi Attack on Abqaiq
Susie Day
You Say You Want a Revolution: a Prison Letter to Yoko Ono
Rich Gibson
Seize Solidarity House
Laura Flanders
From Voice of America to NPR: New CEO Lansing’s Glass House
Don Fitz
What is Energy Denial?
Dan Bacher
Governor Newsom Says He Will Veto Bill Blocking Trump Rollback of Endangered Fish Species Protections
Thomas Knapp
Election 2020: Time to Stop Pretending and Start Over
W. Alejandro Sanchez
Inside the Syrian Peace Talks
Elliot Sperber
Mickey Mouse Networks
September 16, 2019
Sam Husseini
Biden Taking Iraq Lies to the Max
Paul Street
Joe Biden’s Answer to Slavery’s Legacy: Phonographs for the Poor
Paul Atwood
Why Mattis is No Hero
Jonathan Cook
Brexit Reveals Jeremy Corbyn to be the True Moderate
Jeff Mackler
Trump, Trade and China
Robert Hunziker
Fukushima’s Radioactive Water Crisis
Evaggelos Vallianatos
The Democrats and the Climate Crisis
Michael Doliner
Hot Stuff on the Afghan Peace Deal Snafu
FacebookTwitterRedditEmail